Newsfiscal.ai
Assembly Biosciences Announces Dosing of First Participants in Phase 2 Study of ABI-6250 for Chronic HDV
· Published
Article summary
Assembly Biosciences has initiated dosing in a Phase 2 clinical trial for its oral small-molecule entry inhibitor, ABI-6250, targeting chronic hepatitis delta virus (HDV) infection.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…